State Key Laboratory of Oncology in South China, Guangzhou, Guangdong, P.R. China.
Biomarkers. 2010 May;15(3):243-8. doi: 10.3109/13547500903477377.
Oxaliplatin (OXA)-induced carcinoembryonic antigen (CEA) surge was reported to be associated with a clinical benefit. The aim of this study was to investigate the phenomenon of CEA surge in irinotecan-based chemotherapy.
We retrospectively reviewed 132 patients with metastatic colorectal cancer treated with irinotecan-based chemotherapy. Incidence of a CEA surge and chemotherapy efficacy were investigated.
Eleven of 99 eligible patients (11.1%) had CEA surges. None of the 11 patients showed progressive disease (four had a partial response, seven had stable disease).
A CEA surge can be induced by irinotecan-based chemotherapy. An early increase in CEA after irinotecan-based chemotherapy does not usually indicate progression of disease and failure of therapy, and should not lead to a change of chemotherapy.
奥沙利铂（OXA）诱导的癌胚抗原（CEA）升高与临床获益相关。本研究旨在探讨伊立替康为基础的化疗中 CEA 升高的现象。
我们回顾性分析了 132 例接受伊立替康为基础化疗的转移性结直肠癌患者。研究了 CEA 升高的发生率和化疗疗效。
99 例符合条件的患者中有 11 例（11.1%）出现 CEA 升高。这 11 例患者均未出现疾病进展（4 例部分缓解，7 例疾病稳定）。
伊立替康为基础的化疗可诱导 CEA 升高。伊立替康为基础化疗后 CEA 的早期升高通常并不表示疾病进展和治疗失败，不应导致化疗方案的改变。
